Close Menu

NEW YORK (GenomeWeb) – Molecular diagnostics firm Biodesix plans this year to launch a proteomic test for guiding immunotherapy in non-small cell lung cancer patients as it continues to build out its lung cancer offerings.

The company aims to release the test around mid-year, said Gary Pestano, vice president of product development and operations, and will offer it for NSCLC patients who Biodesix's Veristrat test identifies as unlikely to respond to treatment with an EGFR inhibitor.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.